中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 10
Oct.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(10): 2358-2365

Clinical features of non－B， non－C hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.10.013
  • 1.

    School of Medicine，University of Electronic Science and Technology of China，Chengdu 610000，China

  • 2.

    Department of Gastroenterology，Sichuan Provincial People’s Hospital，Chengdu 610000，China

More Information
  • Corresponding author: LI Liangping， 18981838872@163.com （ORCID： 0000－0001－8102－7851）
  • Received Date: 2023-01-16
  • Published Date: 2023-10-30
    Abstract
  •   Objective  To investigate the change in the proportion of non－B， non－C hepatocellular carcinoma （NBNC－HCC） in hepatocellular carcinoma， and to compare and analyze the clinicopathological features of NBNC－HCC.  Methods  A total of 3 090 patients with hepatocellular carcinoma （HCC） who were diagnosed in Sichuan Provincial People’s Hospital from January 2011 to December 2021 were enrolled， and according to the hepatitis markers， they were divided into hepatitis virus infection－associated HCC group with 2 472 patients and NBNC－HCC group with 618 patients. According to the liver disease and metabolic risk factors， the NBNC－HCC group was further divided into metabolic disorder HCC group with 289 patients， alcoholic liver disease （ALD）－associated HCC group with 174 patients， and other HCC group with 155 patients. General information， laboratory markers， and pathological findings were collected from all HCC patients. The Mann－Whitney U test was used for comparison of continuous data between two groups， and the Kruskal－Wallis H test was used for comparison between three groups； the chi－square test was used for comparison of categorical data between groups， and the chi－square trend test was used to investigate the trend of the change in the proportion of NBNC－HCC in HCC.  Results  The proportion of patients with NBNC－HCC in HCC increased from 13.7% in 2011 to 20.1% in 2021 （χ2=5.529， P=0.019）， and compared with the hepatitis virus infection－associated HCC group， the NBNC－HCC group had a significantly higher proportion of patients with diabetes （28.0% vs 10.3%， χ2=129.482， P<0.001） or hypertension （33.2% vs 15.2%， χ2=105.079， P<0.001）， a significantly lower proportion of patients with liver cirrhosis （44.5% vs 68.4%， χ2=122.563， P<0.001） or vascular invasion （20.4% vs 29.6%， χ2=7.749， P=0.005）， and a significantly higher body mass index （BMI） （Z=－4.015， P<0.001）. Compared with the ALD－HCC group， the metabolic disorder HCC group had a significantly higher BMI， a significantly lower FIB－4 index， and a significantly lower proportion of patients with liver cirrhosis （all P<0.05）.  Conclusion  There is a tendency of increase in the proportion of patients with NBNC－HCC in HCC， and NBNC－HCC often coexists with metabolic risk factors such as obesity， diabetes， and hypertension. Patients in the metabolic disorder HCC group may develop liver cancer in the absence of liver cirrhosis or in the early stage of liver fibrosis.

     

    • FullText(HTML)
  • loading
    • References(30)
  • [1]
    LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572－020－00240－3.
    [2]
    GOH GB, CHANG PE, TAN CK. Changing epidemiology of hepatocellular carcinoma in Asia[J]. Best Pract Res Clin Gastroenterol, 2015, 29( 6): 919－ 928. DOI: 10.1016/j.bpg.2015.09.007.
    [3]
    XIAO L, ZHANG RL, ZHANG H, et al. Comparison of the clinical characteristics and survival between Uyghur patients with hepatitis virus－related and non－B, non－C hepatocellular carcinoma in Xinjiang, China[J]. Chin J Cancer Res, 2015, 27( 3): 279－ 287. DOI: 10.3978/j.issn.1000－9604.2015.01.04.
    [4]
    NAGAOKI Y, HYOGO H, ANDO Y, et al. Increasing incidence of non－HBV－ and non－HCV－related hepatocellular carcinoma: single－institution 20－year study[J]. BMC Gastroenterol, 2021, 21( 1): 306. DOI: 10.1186/s12876－021－01884－5.
    [5]
    MCGLYNN KA, PETRICK JL, EL－SERAG HB. Epidemiology of Hepatocellular Carcinoma[J]. Hepatology, 2021, 73 Suppl 1(Suppl 1): 4－ 13. DOI: 10.1002/hep.31288.
    [6]
    TATEISHI R, UCHINO K, FUJIWARA N, et al. A nationwide survey on non－B, non－C hepatocellular carcinoma in Japan: 2011－2015 update[J]. J Gastroenterol, 2019, 54( 4): 367－ 376. DOI: 10.1007/s00535－018－1532－5.
    [7]
    WAKIYAMA S, MATSUMOTO M, HARUKI K, et al. Clinical features and outcome of surgical patients with non－B non－C hepatocellular carcinoma[J]. Anticancer Res, 2017, 37( 6): 3207－ 3213. DOI: 10.21873/anticanres.11682.
    [8]
    GOLABI P, RHEA L, HENRY L, et al. Hepatocellular carcinoma and non－alcoholic fatty liver disease[J]. Hepatol Int, 2019, 13( 6): 688－ 694. DOI: 10.1007/s12072－019－09995－8.
    [9]
    LIN YP, WANG PM, CHUANG CH, et al. Metabolic risks are increasing in non－B non－C early－stage hepatocellular carcinoma: a 10－year follow－up study[J]. Front Oncol, 2022, 12: 816472. DOI: 10.3389/fonc.2022.816472.
    [10]
    KIM J, KANG W, SINN DH, et al. Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non－B non－C hepatocellular carcinoma in Korea[J]. Korean J Intern Med, 2020, 35( 1): 65－ 78. DOI: 10.3904/kjim.2018.040.
    [11]
    Chinese Diabetes Society. Guidelines for the prevention and treatment of type 2 diabetes in china(2020 edition)[J]. Int J Endocrinol Metab, 2021, 41( 5): 482－ 548. DOI: 10.3760/cma.j.cn121383－20210825－08063.

    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志, 2021, 41( 5): 482－ 548. DOI: 10.3760/cma.j.cn121383－20210825－08063.
    [12]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction－associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202－ 209. DOI: 10.1016/j.jhep.2020.03.039.
    [13]
    VITALE A, SVEGLIATI－BARONI G, ORTOLANI A, et al. Epidemiological trends and trajectories of MAFLD－associated hepatocellular carcinoma 2002－2033: the ITA.LI.CA database[J]. Gut, 2023, 72( 1): 141－ 152. DOI: 10.1136/gutjnl－2021－324915.
    [14]
    Chinese Medical Association, Journal of Chinese Medical Association, Chinese Society of Gastroenterology, et al. Guideline for primary care of alcoholic liver disease(2019)[J]. Chin Gen Pract, 2020, 19( 11): 990－ 996. DOI: 10.3760/cma.j.cn114798－20200812－00898.

    中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 酒精性肝病基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19( 11): 990－ 996. DOI: 10.3760/cma.j.cn114798－20200812－00898.
    [15]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol, 2020, 36( 2): 277－ 292. DOI: 10.3969/j.issn.1001－5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36( 2): 277－ 292. DOI: 10.3969/j.issn.1001－5256.2020.02.007.
    [16]
    SHAH AG, LYDECKER A, MURRAY K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2009, 7( 10): 1104－ 1112. DOI: 10.1016/j.cgh.2009.05.033.
    [17]
    JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence－based approach－the ALBI grade[J]. J Clin Oncol, 2015, 33( 6): 550－ 558. DOI: 10.1200/JCO.2014.57.9151.
    [18]
    ZHOU J, ZHOU F, WANG W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71( 5): 1851－ 1864. DOI: 10.1002/hep.31150.
    [19]
    LIU K, MCCAUGHAN GW. Epidemiology and etiologic associations of non－alcoholic fatty liver disease and associated HCC[J]. Adv Exp Med Biol, 2018, 1061: 3－ 18. DOI: 10.1007/978－981－10－8684－7_2.
    [20]
    KANWAL F, KRAMER JR, LI L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71( 3): 808－ 819. DOI: 10.1002/hep.31014.
    [21]
    DAVID D, RAGHAVENDRAN A, GOEL A, et al. Risk factors for non－alcoholic fatty liver disease are common in patients with non－B non－C hepatocellular carcinoma in India[J]. Indian J Gastroenterol, 2017, 36( 5): 373－ 379. DOI: 10.1007/s12664－017－0785－x.
    [22]
    YAN SY, FAN JG. Diagnosis and treatment of hepatocellular carcinoma associated with non－alcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 8): 1748－ 1752. DOI: 10.3969/j.issn.1001－5256.2021.08.002.

    颜士岩, 范建高. 非酒精性脂肪性肝病相关肝细胞癌的诊断和治疗[J]. 临床肝胆病杂志, 2021, 37( 8): 1748－ 1752. DOI: 10.3969/j.issn.1001－5256.2021.08.002.
    [23]
    LEVRERO M, ZUCMAN－ROSSI J. Mechanisms of HBV－induced hepatocellular carcinoma[J]. J Hepatol, 2016, 64( 1 Suppl): S84－S101. DOI: 10.1016/j.jhep.2016.02.021.
    [24]
    YU MW, LIN CL, LIU CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver－related death in men with chronic hepatitis B: A large cohort study[J]. Gastroenterology, 2017, 153( 4): 1006－ 1017.e 5. DOI: 10.1053/j.gastro.2017.07.001.
    [25]
    JIANG LN, LI W, ZHAO JM. Current status and perspectives of the clinical and basic research on concomitant chronic hepatitis B virus infection and nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37( 7): 1489－ 1494. DOI: 10.3969/j.issn.1001－5256.2021.07.001.

    蒋丽娜, 李玮, 赵景民. 慢性HBV感染重叠非酒精性脂肪性肝病临床与基础研究的现状及展望[J]. 临床肝胆病杂志, 2021, 37( 7): 1489－ 1494. DOI: 10.3969/j.issn.1001－5256.2021.07.001.
    [26]
    CHEN CL, YANG HI, YANG WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow－up study in Taiwan[J]. Gastroenterology, 2008, 135( 1): 111－ 121. DOI: 10.1053/j.gastro.2008.03.073.
    [27]
    STINE JG, WENTWORTH BJ, ZIMMET A, et al. Systematic review with meta－analysis: risk of hepatocellular carcinoma in non－alcoholic steatohepatitis without cirrhosis compared to other liver diseases[J]. Aliment Pharmacol Ther, 2018, 48( 7): 696－ 703. DOI: 10.1111/apt.14937.
    [28]
    PERUMPAIL RB, LIU A, WONG RJ, et al. Pathogenesis of hepatocarcinogenesis in non－cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways[J]. World J Hepatol, 2015, 7( 22): 2384－ 2388. DOI: 10.4254/wjh.v7.i22.2384.
    [29]
    WHITE DL, KANWAL F, EL－SERAG HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review[J]. Clin Gastroenterol Hepatol, 2012, 10( 12): 1342－ 1359.e 2. DOI: 10.1016/j.cgh.2012.10.001.
    [30]
    WONG DK, CHENG S, MAK LL, et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis[J]. Clin Gastroenterol Hepatol, 2020, 18( 2): 449－ 456. DOI: 10.1016/j.cgh.2019.06.029.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (194) PDF downloads(35) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return